Comparison of protocols of previous studies evaluating direct glycoprotein-specific PA assays in ITP (that included at least 50 assays in ITP patients) with the current study
Study . | . | Clinical considerations . | Laboratory criteria (ISTH recommendations9 ) . | Sensitivity . | |||||
---|---|---|---|---|---|---|---|---|---|
No. assays in ITP patients . | ASH 2011 guidelines4 . | Adults or children only . | ACD-A anticoagulant . | Recommended blood volume . | Direct test . | Anti-GPIIb/IIIa and GPIb/IX . | Central laboratory . | ||
Brighton et al, 19966 | 81 | x | ? | x | ? | ✓ | ✓ | ✓ | 49% |
Warner et al, 199922 | 56 | x | ? | ✓ | ? | ✓ | ✓ | ✓ | 66% |
Fabris et al, 200211 | 65 | x | ? | ? | ? | ✓ | ✓ | ✓ | 60% |
McMillan et al, 200314,* | 282 | ✓ | ✓ | x | ? | ✓ | ✓ | ✓ | 55% |
Chan et al, 200323 | 59 | x | x | ✓ | ? | ✓ | x | ✓ | 73% |
Fabris et al, 200416 | 50 | x | ✓ | ? | ? | ✓ | ✓ | ✓ | 50% |
Davoren et al, 200524 | 216 | x | x | x | ✓ | ✓ | ✓ | ✓ | 53% |
Chen et al, 201225 | 64 | x | ? | x | ? | ✓ | x | ✓ | 39% |
Najaoui et al, 201226 | 240 | x | ? | x | ? | ✓ | ✓ | ✓ | 54% |
He et al, 201327,* | 50 | ✓ | x | x | x | ✓ | ✓ | ✓ | 44% |
Zhao et al, 201528 | 71 | ✓ | x | x | x | ✓ | ✓ | ✓ | 39% |
Porcelijn et al, 201829 | 149 | ✓ | ? | x | ? | ✓ | ✓ | ✓ | 81% |
Current study | 360 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 90% |
Study . | . | Clinical considerations . | Laboratory criteria (ISTH recommendations9 ) . | Sensitivity . | |||||
---|---|---|---|---|---|---|---|---|---|
No. assays in ITP patients . | ASH 2011 guidelines4 . | Adults or children only . | ACD-A anticoagulant . | Recommended blood volume . | Direct test . | Anti-GPIIb/IIIa and GPIb/IX . | Central laboratory . | ||
Brighton et al, 19966 | 81 | x | ? | x | ? | ✓ | ✓ | ✓ | 49% |
Warner et al, 199922 | 56 | x | ? | ✓ | ? | ✓ | ✓ | ✓ | 66% |
Fabris et al, 200211 | 65 | x | ? | ? | ? | ✓ | ✓ | ✓ | 60% |
McMillan et al, 200314,* | 282 | ✓ | ✓ | x | ? | ✓ | ✓ | ✓ | 55% |
Chan et al, 200323 | 59 | x | x | ✓ | ? | ✓ | x | ✓ | 73% |
Fabris et al, 200416 | 50 | x | ✓ | ? | ? | ✓ | ✓ | ✓ | 50% |
Davoren et al, 200524 | 216 | x | x | x | ✓ | ✓ | ✓ | ✓ | 53% |
Chen et al, 201225 | 64 | x | ? | x | ? | ✓ | x | ✓ | 39% |
Najaoui et al, 201226 | 240 | x | ? | x | ? | ✓ | ✓ | ✓ | 54% |
He et al, 201327,* | 50 | ✓ | x | x | x | ✓ | ✓ | ✓ | 44% |
Zhao et al, 201528 | 71 | ✓ | x | x | x | ✓ | ✓ | ✓ | 39% |
Porcelijn et al, 201829 | 149 | ✓ | ? | x | ? | ✓ | ✓ | ✓ | 81% |
Current study | 360 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 90% |
✓, yes; x, no; ?, notspecified.
Followed ASH 1996 clinical practice guidelines.